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Multifunctional 3D-Printed Patches for Long-Term Drug 
Release Therapies after Myocardial Infarction
Rubina Ajdary, Nazanin Zanjanizadeh Ezazi, Alexandra Correia, Marianna Kemell,  
Siqi Huan, Heikki J. Ruskoaho, Jouni Hirvonen, Hélder A. Santos,* and Orlando J. Rojas*
A biomaterial system incorporating nanocellulose, poly(glycerol sebacate), 
and polypyrrole is introduced for the treatment of myocardial infarction. 
Direct ink writing of the multicomponent aqueous suspensions allows 
multifunctional lattice structures that not only feature elasticity and electrical 
conductivity but enable cell growth. They are proposed as cardiac patches 
given their biocompatibility with H9c2 cardiomyoblasts, which attach exten-
sively at the microstructural level, and induce their proliferation for 28 days. 
Two model drugs (3i-1000 and curcumin) are investigated for their integra-
tion in the patches, either by loading in the precursor suspension used for 
extrusion or by direct impregnation of the as-obtained, dry lattice. In studies 
of drug release conducted for five months, a slow in vitro degradation of the 
cardiac patches is observed, which prevents drug burst release and indicates 
their suitability for long-term therapy. The combination of biocompatibility, 
biodegradability, mechanical strength, flexibility, and electrical conductivity 
fulfills the requirement of the highly dynamic and functional electrorespon-
sive cardiac tissue. Overall, the proposed cardiac patches are viable alterna-
tives for the regeneration of myocardium after infarction through the effective 
integration of cardiac cells with the biomaterial.
DOI: 10.1002/adfm.202003440
fields.[1,2] Nanocellulose has similarities 
with the extracellular matrix (ECMs), it is 
biocompatible and can be assembled in 
highly porous structures.[3] Aqueous sus-
pensions of nanocellulose are shear-thin-
ning, which facilitate extrusion via direct 
ink writing (DIW),[4–6] which has been 
used to develop highly porous (99.7%) 
and swellable (447 g water g−1) scaffolds.[7] 
Moreover, they have been proven to be 
nontoxic, highly stable and compatible 
with fibroblast,[4] H9c2 cardiac myoblast,[3] 
and Murine preosteoblastic (MC3T3-E1) 
cells.[8] Notably, to fully exploit the prop-
erties of scaffolds based on nanocellu-
lose, consideration should be given to 
the processing technique. In this respect, 
several approaches have been introduced, 
including gel casting,[9] electrospinning,[10] 
and 3D printing.[4] The latter approach is 
particularly useful to gain control on the 
morphological organization of the scaf-
fold, including its geometry, gradient 
porosity, and pore orientation, and also to 
achieve tunable mechanical properties.[11,12]
Although 3D printing has opened new avenues for the 
development of tailorable structures, several challenges still 
remain. They include the need to optimize the composition 
to achieve 3D-printable inks, the high water content of the 
1. Introduction
Nanofibrillated cellulose (CNF) has emerged as a promising 
nanostructured material exhibiting versatile properties for 
a wide range of applications, in particular in the biomedical 
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respective gels and the extensive shrinkage of the obtained 
structures upon removal of the water.[13] The potential of 
nanocellulose as a highly stable, 3D printed material has 
been demonstrated for cell culturing scaffolds;[3] however, 
such structures lack some critical properties such as elasticity. 
Thus, additional components are required to enhance, tune, 
or facilitate given properties in the nanocomposite and to 
match the targeted application. Here, poly(glycerol sebacate) 
(PGS), a biodegradable and cost-effective polymer commonly 
used in biomedical devices, was combined with nanocellulose 
to alter its mechanical behavior, particularly to enable scaf-
folds with elasticity and flexibility. The application of PGS 
targets the soft tissue along with tailorable mechanical prop-
erties as defined by the synthesis method.[14–16] Importantly, 
in a recent study,[17] we reported cardiac patches based on 
PGS loaded with polypyrrole (PPy), a heterocyclic conductive 
polymer,[17,18] which facilitated both cytocompatibility and elec-
trical conductivity.[19–21]
As a new development of this earlier work, we propose the 
incorporation of nanocellulose not only to facilitate direct ink 
writing but to act as active component in the scaffolds used 
as cardiac patches. Such materials are of high interest in the 
treatment of cardiovascular diseases, which according to the 
World Health Organization (WHO), represent the principal 
cause of deaths worldwide (31% of the total), amounting to 
17.9 million patients per year.[22] As the adult human hearts 
possess a negligible regenerative capacity, cardiomyocyte 
loss in response to myocardial infarction leads to scar forma-
tion, remodeling of the surrounding myocardium, progres-
sive impairment of cardiac function, and eventually to heart 
failure.[23] Solutions, such as cell-based therapy and organ 
transplantation have been implemented;[24–27] however, they 
are often associated with complications, such as deficient 
cell injection, immune rejection, and insufficient nutrition 
supply.[19,28,29]
These limitations have encouraged the development of 
alternative approaches to regenerate the infarcted heart 
tissue, for example, through the integration of cardiac cells 
and biomaterials.[28] Related biomaterials can perform as 
mechanical support for cells and promote their reorganiza-
tion into a functional tissue.[30] Thus, there is a demand for 
scaffolds that are similar to the ECM and mimic the original 
tissue, e.g., by holding cardiomyocytes and other cardiac 
cells, while facilitating myocardial regeneration.[31,32] In addi-
tion to biocompatibility and biodegradability, such cardiac 
scaffolds should fulfill several other properties, including 
mechanical strength and electrical conductivity, so that the 
dynamic functions of electroresponsive cardiac tissue are 
maintained.[17,33]
The materials used for cardiac tissue engineering can be 
of natural origin (such as gelatin,[29,33,34] alginate,[35,36] chi-
tosan,[32] collagen,[17,35] bacterial nanocellulose,[37] and fibrin),[38] 
synthetic (including polyurethane,[39,40] polycaprolactone,[40] 
poly(lactic acid),[41,42] poly(glycolic acid)),[42] as well as composite 
and hybrid materials,[17] which combine natural, synthetic or 
metallic compositions.[43,44] In the first category, some biopoly-
mers have the advantage of being similar to the ECM; however, 
the balance between swelling stability and mechanical strength 
remains challenging.[45]
According to previous studies, crosslinking or addition 
of complexing agents enhances the mechanical strength of 
natural polymers, as well as their stability in the given scaf-
fold.[46,47] Unfortunately, the most widely used crosslinkers 
in biomedical applications, namely, glutaraldehyde and gen-
ipin, are cytotoxic and the removal of unreacted molecules 
become a necessity to facilitate cell growth.[48] Overall, we 
study 3D-printed cardiac patches based on nanocellulose, PGS 
and PPy, which were tested for load and release of two model 
drugs. The drug selection was in accordance with the antioxi-
dant and anti-inflammatory activity (curcumin),[49,50] as well 
as the efficacy in promoting myocardial repair after myocar-
dial infarction and other injuries (3i-1000).[17,51–53] These drugs 
were loaded in the ink before 3D printing (ink-loaded) and also 
by immersion in the drug solution of the ready-made patches 
(immersion-loaded). In addition, the two methods were tested 
by sequentially applying ink-loading and immersion-loading 
(referred to as ink-immersion loading). The release profiles 
of these systems were monitored for five months. This work 
follows our recent efforts confirming the biocompatibility of 
H9c2 cardiomyoblast with highly stable nanocellulose scaf-
folds,[3] as well as the promising results related to H9c2 car-
diomyoblast−biomaterial interactions in PGS-collagen-PPy 
2D-casted films.[17] Thus, we introduce a suitable composition 
in the form of 3D-printed cardiac patches based on plant-
based nanocellulose that fulfills requirements such as biocom-
patibility, elasticity, and electrical conductivity, comparable to 
those of native cardiac tissue.[54] The morphology, microstruc-
ture, and porosity of the biocomposites were examined and the 
biological responses evaluated through cell viability, prolifera-
tion, and attachment.
2. Results and Discussion
2.1. Elastic and Conductive Nanocellulose-Based  
Composite Patches
2.1.1. Ink Composition
Several compositions of 2,2,6,6-tetramethylpiperidine-1-oxyl 
radical-oxidized nanocellulose (TOCNF), pre-PGS, and PPy 
were tested to provide a suitable shear flow behavior and to 
endow the printed patches with mechanical integrity and 
electrical conductivity. As indicated in Figure  1a, TOCNF 
was used as principal component and support phase for pre-
PGS and PPy, which were added to provide elasticity and 
conductivity. According to differential scanning calorimetry, 
no thermal degradation occurred for neat TOCNF or sample 
5% 1:2 at the processing temperature (Figure S1, Supporting 
Information). All inks were shear thinning, with a dominant 
elastic behavior (Figure S2, Supporting Information). The 
3D-printed patches contained over 95% solvent, leading to 
an extensive shrinkage upon drying. To limit such effect, the 
samples were freeze-dried, resulting in the preservation of the 
structure and its porosity, prior to the curing of pre-PGS in 
vacuum oven at 120 °C for 48 h. The patches underwent ≈5% 
and 14% shrinkage after freeze-drying followed by pre-PGS 
curing (vacuum oven), respectively (Figure 1b–d).
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2.2. 3D-Printed Patches
2.2.1. Patch Morphology
Transmission electron microscopy (TEM) revealed the typical 
morphology of the cellulose nanofibrils (TOCNF), displaying 
a high axial aspect, Figure 2 (left). The biocomposite systems 
used for 3D printing included the negatively charged nano-
cellulose and the cationic mixture consisting of pre-PGS and 
PPy, which formed interfacial electrostatic complexes (shown in 
Figure  2 (right) is the system labeled as “5% 1:2” (PPy w/v%, 
PGS-PPy:TOCNF), see legend of Figure  1 for nomencla-
ture).[21][55] After curing at high temperature and under vacuum, 
the PGS component endows the TOCNF-based system with 
elasticity.
2.2.2. Microstructure and Porosity
The nanocellulose-based scaffolds displayed interconnected 
pores that are expected to facilitate a suitable environment 
for cells to grow and interact (Figure 3a).[3] Single component 
Adv. Funct. Mater. 2020, 2003440
Figure 1. a) Schematic illustration (not to scale) of TOCNF, pre-PGS, and PPy used in the formulation of DIW inks and 3D-printed scaffolds b) before and 
c) after freeze-drying. d) Scaffold after pre-PGS curing for 48 h at 120 °C. e) 3D printed samples of given component ratio, wet and cured (the % figure 
corresponds to PPy % and the ratio refers to the relative volume of pre-PGS-PPy to weight of TOCNF). The scale bar in (b)–(e) corresponds to 1 cm.
Figure 2. TEM images of the samples comprising a) neat TOCNF and b) 3D printed TOCNF composite with PGS and PPy after curing (5% 1:2 system 
according to the nomenclature presented in the legend of Figure 1). The scale bar corresponds to 100 nm.
www.afm-journal.dewww.advancedsciencenews.com
2003440 (4 of 10) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
TOCNF scaffolds (Figure  3a), were remarkably more porous 
(94 ±  1% porosity) compared to those produced with PGS-PPy 
(Figure 3b) or with the multicomponent counterparts. Overall, 
TOCNF enhances the porosity and permeability of the struc-
ture, which are factors that favor cells attachment.[3] Figure 3c–f 
compares microstructures obtained before and after PGS syn-
thesis. Phase separation of TOCNF and pre-PGS-PPy is evi-
dent, Figure  3c,e. After pre-PGS curing, the phases formed a 
homogenous biocomposite structure with 78 ± 2% porosity.
2.2.3. Electrical Conductivity and Mechanical Properties
Systems containing 1% PPy were not electrically conductive; 
therefore, we focus the discussion on samples with a higher 
PPy loading, which were electrically conductive. We note that 
a high nanocellulose loading produced patches with an uneven 
conductivity, as measured in different areas of the structure, 
which is explained by the pores generated upon removal of 
water, as expected.[56] As shown in Table 1, The 5% 1:2 system 
presented an electrical conductivity of 34 mS cm−1. This value 
is relatively lower than those measured for nanocellulose-PPy 
composites previously prepared from precursors such as hydro-
gels, sponges, and coatings (electrical conductivity in the range 
of ≈80–150 mS cm−1), suitable for paper-based energy storage 
devices and composites for nerve regeneration.[57–59] However, 
for the present purpose, the produced patches were determined 
to have a suitable conductivity.
Turning our attention to the mechanical strength of the 
patches, we note that the elastic modulus of human myocar-
dium ranges from 0.02 to 0.5  MPa,[15] while the values for 
pure PGS varies between 0.056 and 1.5  MPa, depending on 
Adv. Funct. Mater. 2020, 2003440
Table 1. Main characteristics of patches of given composition.








TOCNF 0 0.2 ± 0.04 2 94 ± 1
5% 1:4 3 ± 1.3 –a) – –
5% 1:2 34 ± 2.7 0.6 ± 0.16 18 78 ± 2
a)“–”: Not available.
Figure 3. Scanning electron microscope (SEM) images of patches produced with a) neat TOCNF; b) casted and cured PGS-PPy 5%; c) 5% 1:4 and 
e) 5% 1:2 before PGS synthesis, showing phase separation of TOCNF and pre-PGS. d) 5% 1:4 and f) 5% 1:2 after pre-PGS curing, illustrating the forma-
tion of PGS-PPy-TOCNF biocomposite. The scale bars correspond to 100 µm.
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the curing time.[60] The Young’s modulus of the biocomposites 
increased considerably (three-fold) upon addition of TOCNF, 
reaching a value comparable with that of the human myocar-
dium. Compared to pure PGS, the presence of nanocellulose 
limits the elongation of the composite; however, the meas-
ured value still meets the performance criteria, as indicated in 
previous reports.[61,62] Moreover, compared to the porosity of 
patches formed from neat TOCNF, the values corresponding to 
systems containing PGS and PPy decreased by ≈17%. However, 
this reduction in porosity did not have a significant impact on 
cell–biocomposite interactions, as discussed in later sections.
2.2.4. Degradation and Swelling of 3D Printed Scaffolds
The structural stability, extent of biomaterial degradation and 
its rate are essential factors for drug administration.[63] As such, 
patch swelling (absorption capacity) and degradation rate in 
aqueous media were examined during 21 days using buffered 
media at two pH values. Degradation in MES (pH 6) was faster 
compared to that in Phosphate-buffered saline (pH 7.4), which 
occurred only after 14 days, Figure 4a. In general, the presence of 
TOCNF did not significantly affect the degradation in 2-(N-mor-
pholino)ethanesulfonic acid buffer, but a higher degradation in 
PBS (pH 7.4) was observed at low TOCNF loading. Despite the 
absence of crosslinker, the 3D biocomposites were strongly net-
worked and showed 6–7% degradation based on the initial mass. 
According to previous studies, highly crystalline cellulose struc-
tures prevent degradation, which would otherwise occur by enzy-
matic activity or a combination of autocatalytic oxidation and 
hydrolytic mechanisms.[64,65] As shown in our previous research, 
the addition of PPy does not affect the degradation rate;[17] there-
fore the degradation mostly involved the PGS component.[66]
Figure  4b shows the swelling of the patches, which indi-
cated >200% water absorption with respect to the initial mass, 
highlighting the contribution of TOCNF (systems with cellu-
lose nanofibrils alone absorbs more than 1000% its dry mass) 
(Figure S3, Supporting Information).[3] Owing to the carboxylic 
groups present in TOCNF, an extensive swelling in MES was 
observed at high TOCNF loadings (days 1, 14). Swelling is an 
essential factor as it relates to the ability to absorb the fluid 
medium after implantation, which facilitates nutrient and 
oxygen transport inside the system, as well as cell infiltration.[18] 
In the medium, the patch must be stable even in the swollen 
state. In the present system, owing to the presence of highly 
stable TOCNF, the patches underwent swelling while main-
taining microstructural integrity.
2.2.5. Cell Viability, Proliferation, and Attachment  
of the 3D Printed Scaffolds
The biocompatibility of 3D printed composites undergoing 
degradation was examined by using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium Bromide (MTT) assay and com-
pared with a positive control (empty incubated medium). As 
shown in Figure 5a, the degradation of the different patches did 
not affect the viability of H9c2 cardiomyoblast. No cytotoxicity 
was detected during 28 days; even at day one, a slight prolif-
eration was observed for cells in the vicinity of the degraded 
biocomposites.
As illustrated in Figure 5b, all types of 3D printed biocompos-
ites showed an ability to host cardiomyoblasts for proliferation. 
No significant differences were observed in H9c2 cell prolifera-
tion for patches at the different PPy loadings. We reported cell 
proliferation and attachment of cells on TOCNF[3] and PGS-col-
lagen-PPy 2D heart patches.[17] Here, TOCNF was freeze-dried 
and placed in a vacuum oven at 120 °C under low pressure, e.g., 
to maintain the same conditions as those used in the synthesis 
of the biocomposites. The standard deviation shows that the 
proliferation of the H9c2 cells on 3D-printed composites were 
in the same range as that for the TOCNF porous structure. The 
cells proliferated around twice in each two weeks. This result 
points to the capability of the scaffolds to both, host the cells 
and to create a suitable environment for proliferation. Cell−
biocomposite interactions for 4 days indicated that the patches, 
with their porous structures (scanning electron microscopy, 
SEM), allowed good attachment. Cell bodies assembled on the 
pore surface and elongated on the pore walls with high exten-
sion and adhesion. Figure  5c,d illustrates the empty control 
sample and the cell-seeded biocomposite, respectively. The 
results confirm the cell viability tests and show a positive inter-
action between H9c2 cardiomyoblast and the 3D-printed, con-
ductive patch following cell infiltration. The TOCNF and PGS 
hydrophilicity, high porosity, and surface area make the system 
suitable for cell attachment while remaining viable.
Adv. Funct. Mater. 2020, 2003440
Figure 4. a) Degradation and b) swelling of 3D-printed cardiac patches measured in PBS (pH 7.4) and MES (pH 6) buffers.
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2.2.6. Drug Release
The release profiles of the two model drugs tested were deter-
mined for composite patches following ink- and immersion-
loading. The experiments included single drug delivery and 
codelivery in PBS physiological solution (pH 7.4) and MES 
buffer corresponding to the pH of typical infarcted heart 
tissue (pH 6).[67] Curcumin was used as an antioxidant and 
anti-inflammatory agent[68,69] while 3i-1000 is an inhibitor of 
GATA4-NKX2-5 interaction, and used for repair of myocardium 
after injuries.[52,70,71] The drug loading was calculated from the 
amount of residual drug in the system extracted in ethanol. The 
ink-loading approach did not produce a significant drug incor-
poration. For the other systems, the loading values were calcu-
lated on the basis of mass was 1.6−0.8% and 0.2% for 3i-1000 
and curcumin, respectively. Both drugs are hydrophobic and 
bear negative surface charges at pH 7.4 and 6.[69] Our results 
indicate that for all tested media conditions, the cumulative 
released amount of curcumin and 3i-1000 was <2% and ≈12%, 
respectively (Figure  6). The low curcumin release is likely 
related to its degradation, especially at 37 °C and pH 7.4 (physi-
ological pH).[68] In MES (corresponding to a lower pH = 6), 
the release of curcumin was still low, but higher compared to 
that determined at physiological pH. As expected, 3i-1000 was 
released more extensively from patches that were immersion-
loaded (Figure S4a, Supporting Information). The release of the 
drug from the structure is likely related to the degradation of 
the PGS component, which depends on the conditions used for 
PGS synthesis, such as pressure and temperature.[72] The PGS-
TOCNF-PPy patches show a slow release of the model drugs, 
which degraded by 8% after 21 days (Figure 6b).
3. Conclusion
In this study, drug-loaded 3D-printed conductive patches were 
fabricated for intended uses in cardiac conditions. Porous 
nanocellulose, elastic PGS, and conductive PPy were incor-
porated in biocomposites with no need for crosslinkers. The 
cardiac patches showed high biocompatibility with cardiomyo-
blasts and induced cell proliferation for 28 days. Cells attached 
on the microstructure followed the same shape and pattern as 
those of the microstructural support. The patches were loaded 
inside the pores, which mostly controls the release, and also 
inside the structure, which is subjected to the degradation of 
PGS. The slow degradation of the cardiac patches is expected 
to prevent burst release and make them suitable for long-term 
codelivery of drugs for therapies after myocardial infarction
4. Experimental Section
Materials: Preparation of TEMPO oxidized nanocellulose is explained in 
details in the Supporting Information. Glycerol 85% was purchased from 
Yliopiston Apteekki, Finland. Sebacic acid, Pressed pellets of polypyrrole 
and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
were obtained from Sigma Aldrich and Hank’s buffered salt solution 
(HBSS) 10× was obtained from Gibco Life Technologies. Curcumin was 
purchased from Chemcruz.
Design and Fabrication of Elastic and Conductive Patches—Ink 
Composition: Prepolyglycerol sebacate (pre-PGS) prepared as described 
in the previous work. Briefly, equimolar solutions of sebacic acid 
and glycerol (0.05 m) were mixed at 120 °C under argon gas for 24 h. 
Afterward, tip-sonicated PPy dispersion in tetrahydrofuran (THF) was 
added (1 or 5% w/v), and the mixture was stirred for 48 h at room 
temperature. TOCNF suspension was then mixed (IKA T-25 Ultra-Turrax) 
Adv. Funct. Mater. 2020, 2003440
Figure 5. a) Cytotoxicity and b) H9c2 cardiomyoblast proliferation during 28 days analyzed by MTT and alamarBlue assays, respectively. Blank incu-
bated medium was used as a positive control for cytotoxicity tests (n = 4). Cell attachment of c) control sample 5% 1:2 and d) 5% 1:2 sample, containing 
H9c2 cells. The magnification for (a) and (b) is 1000× .
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to obtain nanocellulose-based ink of varying ratios, 0:1 (pre-PGS-PPy: 
TOCNF), 1:2 and 1:4 (Table 2).
Design and Fabrication of Elastic and Conductive Patches—3D Printing 
of the Composite Ink: A BIO X Bioprinter (CELLINK, Gothenburg, 
Sweden) equipped with pneumatic print-head was used to print the 
cardiac patches. All samples were designed to be rectangular grid with a 
rectilinear infill pattern and 25% infill density. The system utilized clear 
pneumatic 3 mL syringes and sterile blunt needles, 18G from CELLINK, 
with the nozzle tip size of 0.84  mm. The solid support used for 3D 
printing consisted of plastic Petri dishes (100 mm diameter).
Printing parameters, including nozzle size, print speed, and extrusion 
pressure were adjusted to achieve suitable conditions for 3D printing 
of nanocellulose-based cardiac patches of high visual quality. After 3D 
printing, the samples were frozen overnight at −18 °C followed by freeze-
drying with a FreeZone 2.5 L Benchtop Freeze Dryer for 48 h at −49 °C 
and 0.05 mbar to avoid extensive biocomposite shrinkage upon removal 
of water. Following, PGS synthesis from the prepolymer was achieved by 
curing the patches for 48 h in a vacuum oven at 120 °C.
Characterization of 3D Printed Patches—Transmission Electron 
Microscopy: TEM imaging of nanocellulose-based cardiac patches was 
performed with a JEM-2800 (JEOL) high-resolution TEM microscope 
operating at 200  kV. A small piece of porous nanocellulose-based 
structure was embedded in epoxy resin to form a block surrounding the 
sample. The block was trimmed in the shape of trapezoid to ease slicing 
in thin sections. An Ultramicrotome Leica UC7 with a Diatome Cryo Wet 
35 diamond knife was used to cut 3D printed cured samples of 50 nm 
thickness. The serial sections were separated by an eyelash brush and 
directly collected from the surface of water by using an iron ring on the 
TEM grid.
Characterization of 3D Printed Patches—Microstructure: The 
microstructure of extruded patches after freeze drying was observed by 
SEM (Zeiss Sigma VP, Germany and Hitachi S-4800, Japan) operated 
under vacuum and at an accelerated voltage of 5–10 kV. To examine the 
microstructure in the absence of TOCNF, the PGS-PPy 5% was casted 
in glass Petri dishes and cured for 48 h at 120 °C. The dry samples were 
fixed on metal stubs using carbon tape and coated with a 4–5 nm layer 
of gold palladium alloy using a LEICA EM ACE600 sputter coater.
Characterization of 3D Printed Patches—Porosity: Ethanol replacement 
method was used to evaluate the porosity of 3D printed samples.[18,73] In 
this method, dry 3D printed cubes (1 cm × 1 cm × 1 cm) were immersed 
in excess pure ethanol for 48 h. The weight change was monitored 
until constant weight. The porosity Φ was then calculated following 
Equation  (1), where msat is the weight of the sample saturated with 
ethanol, md is the dry mass, ρ is the density of ethanol, and V is the 






ρ( ) ( )Φ = −

 ×  (1)
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Figure 6. SEM images of the surface of a) drug-free and, b) drug-loaded biocomposites (1000× magnification, scale bar of 10 µm). Cumulative drug 
(3i-1000 and curcumin) release profiles from the porous biocomposites after ink-immersion loading using a c) single-drug or d) coloading (3i-100/
curcumin) in PBS (pH 7.4, square symbols) and MES (pH 6, circle symbols). Statistical data were obtained by one-way analysis of variance (ANOVA) 
with a level of significance at probabilities of **p < 0.01 and ***p < 0.001.
Table 2. Ink composition in 3D printed cardiac patches.
Sample PPy [w/v %] Pre-PGS:TOCNF volume-to-weight ratio
TOCNF 0 0:1
1% 1:2 1 1:2
1% 1:4 1 1:4
5% 1:2 5 1:2
5% 1:4 5 1:4
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Characterization of 3D Printed Patches—Mechanical Properties: 
Samples were 3D printed with 100% infill and gauge length of 50  mm 
according to ASTM A370 standard. The tensile properties were tested 
with a Universal Instron 4240 testing machine using 100 N load. The test 
speed was 3 mm min−1, and the gauge length was 30 mm. Before any 
tests, the 3D-printed samples were equilibrated for 24 h in a room kept 
at constant temperature (23 °C) and 50% humidity.
Characterization of 3D Printed Patches—Conductivity: A four-point 
probe test unit (Jandel Model RM3000), which combined a constant 
current source and a digital voltmeter, was used to measure the sheet 
resistance of the cardiac patches. 3D-printed grid lattice structures 
with 25% infill and 1 mm thickness were used for the conductivity 
measurements. The conductivity was calculated using Equation  (2), 
where R corresponds to Ohms square−1 and t is sample thickness in 
cm. A caliper was used to measure the thickness of each sample. The 
reported values are the average of 10 measurements on different spots 
of the sample[17]
R t
Conductivity Scm 11( ) = ×−  (2)
Characterization of 3D Printed Patches—Degradation and Swelling 
of 3D printed Scaffolds: For degradation and swelling studies of the 
conductive patches, samples were cut with the same sizes and weighted 
(W0) (four replicates). They were immersed in 3  mL buffer solutions, 
MES (pH 6), and PBS (pH 7.4) for 21 days at 37 °C. At each time point, 
samples were taken from the buffer, and the excess water on the surface 
was wiped with filter paper and weighted in the wet state (Ws). The pH 
of the samples was checked for each buffer. The samples were dried at 
37 °C for 24 h and weighted again in the dry state (Wd). The % swelling 


















Characterization of 3D Printed Patches—Cell Viability, Proliferation, and 
Attachment: The cardiomyoblast−biocomposite interactions were studied 
following our previous works explained in the Supporting Information.[3,17] 
Also, cell attachment on the 3D-printed 5% 1:2 patch was studied by 
SEM during 4 days. First, samples were sterilized by UV light for 3 h 
and trapped in the bottom of the 48-well plates by Pyrex cylinders and 
immersed inside Dulbecco’s Modified Eagle’s Medium with 10% of fetal 
bovine serum, with 1% (w/v) l-glutamine, 1% (w/v) non-essential amino 
acids, and penicillin-streptomycin (100 IU mL−1) for 24 h before 20 000 
H9c2 cells were seeded on top of each sample. At each time point, each 
sample was washed twice with PBS (pH 7.4), and attached cells were 
fixed with 2.5% glutaraldehyde in PBS at 37 °C for 30  min, and then 
washed gently with PBS (pH 7.4) three times before post-fixation with 
1% of osmium tetroxide in PBS for 1 h. Samples were dehydrated using 
50%, 70%, 96%, and 100% of EtOH and dried by critical point drying 
method and later coated with a 4 nm layer of gold palladium alloy using 
a LECIA EM ACE600 sputter coater and imaged by SEM (Zeiss Sigma VP, 
Germany) operated under vacuum and at an accelerated voltage of 5 kV.
Drug Loading and Release: Pre-PGS was prepared by polycondensation 
of equimolar mixtures of sebacic acid and glycerol at 120 °C in neutral 
condition for 24 h. The prepolymer was dissolved in THF and 5% w/v 
PPy were tip sonicated and added to the mixture. The suspension was 
stirred for 48 h in room temperature before adding TOCNF yielding 
pre-PGS-PPy:TOCNF (1:2) in a glass bottle. This suspension (ink) 
was homogenized and divided into two different series to produce 
the respective patches, with and without drug. They were transferred 
into large syringes and loaded with 3i-1000 (2  mg mL−1), curcumin 
(2  mg mL−1), and the 3i-1000/curcumin (1:1) mixture (coloading) 
(2  mg mL−1) all in ethanol. Syringes were kept on a shaker for 2 h at 
room temperature. The ink samples (drug-loaded or drug-free) were 
transferred into clear pneumatic 3  mL syringes, and cylinders were 
printed with 100% infill of grid lattice pattern (patches); a needle size of 
0.84 mm was used in the bioprinter (ink loaded samples). Samples were 
immediately frozen and freeze-dried at −49 °C for 48 h. The two types of 
3D-printed patches were cured in a vacuum oven for 48 h at 120 °C.
Patches that were subjected to immersion-loading (Figure S5a, 
Supporting Information) and combination of immersion-loading and 
ink-loading (Figure S5b, Supporting Information) were immersed in 
drug solutions in EtOH (2  mg mL−1) for 2 h in a shaker operated at 
600 rpm and washed once with MQ-water. Following, the samples were 
immersed in 10 mL of MES medium (pH 6) and PBS (pH 7.4). At given 
time periods, 1  mL of each media was replaced by fresh medium (to 
maintain a constant volume). Drug release was analyzed for five months 
by using high-performance liquid chromatography (HPLC) (Agilent 
1260, Agilent Technologies, USA) with a LC column (100 × 4.6  mm, 
3 µm, Gemini NX-C18, Phenomenex, Denmark), using a mobile phase 
comprising 0.1% of phosphoric acid (PA):acetonitrile (ACN) (75:25 v/v), 
a flow rate of 1  mL min−1 and injection volume of 20 µL. The column 
operated at 25 °C and detection wavelength of 280 nm. For calculating 
the drug release, the total area under the peaks for 3i-1000 and curcumin 
were used after each measurement.
Characterization of 3D Printed Patches—Statistical Analyses: The 
results were reported as mean ± standard deviations (S.D.) of three to 
four independent sets of measurements. Statistical analysis was based 
on a one-way analysis of variance (ANOVA) with a level of significance 
set at probabilities of *p < 0.05, **p < 0.01, ***p < 0.001, examined with 
OriginPro8.6 software.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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